Disclosure: This site may earn affiliate commissions when you click provider links. This doesn't affect our recommendations. Learn more
We compared Hims vs Ro on pricing, medications, insurance help, and support. Both stock Wegovy, Zepbound, and Foundayo. See which wins for you.
If you're comparing Hims vs Ro for weight loss, you're choosing between two of the most-searched GLP-1 telehealth providers, and for good reason: both are large, well-funded platforms with national reach and polished apps. As of October 2026, their brand-name catalogs have fully converged, and so has most of their medication pricing. Both stock Wegovy (pill and pen), Zepbound, Foundayo, and now Ozempic off-label, and both are now brand-name only. The differences sit elsewhere: Hims runs an official Novo Nordisk partnership and a flat, no-prepay membership, while Ro adds active insurance coordination, a more built-out support layer, and a membership that gets cheaper the longer you prepay. The bottom line: if you have insurance you want to use, Ro is the stronger pick. If you're paying out of pocket, both are competitive: pick on app experience, support depth, and whether you're willing to prepay for a lower membership rate. Here's the full breakdown, including what the clinical trials behind these medications actually show.
Last verified: 2026-10-07 by RxPickr Editorial Team. Every monthly price below was confirmed against each provider's published pricing page in our October 2026 pricing refresh. Cancellation and insurance policy claims were checked against each provider's published terms and help pages on 2026-07-10 and were not re-verified this cycle. We re-verify pricing monthly. Our full methodology is at How we rate providers.
Answer 10 questions and we'll match you with the best GLP-1 provider for your situation.
Take the free quiz →| Hims (hims.com) | Ro (ro.co) | |
|---|---|---|
| Price (verified October 2026) | Wegovy pill $149–$299/mo by dose, Foundayo from $149/mo, Zepbound $299–$449/mo by dose, all + $149/mo membership | Wegovy pill $149–$299/mo by dose, Wegovy pen $199/mo starter promo then $349–$399/mo, Zepbound $299–$449/mo by dose, all + $149/mo membership (as low as $74/mo with a 12-month prepay) |
| Medication options | Wegovy (pill + pen), Foundayo, Zepbound (vial + KwikPen), Ozempic (off-label, plus a new oral Ozempic Pill) | Wegovy (pill + pen), Zepbound KwikPen, Foundayo, Ozempic (off-label, near-retail pricing); brand-name only |
| Insurance support | No prior auth assistance | Yes: insurance concierge verifies benefits and submits prior auth (Wegovy pen, Zepbound pen, Ozempic) |
| Support level | Async messaging with care team | Unlimited provider messaging, 24/7 care team access, 1:1 health coaching (per ro.co, September 2026) |
| Cancellation | Cancel 48+ hours before next order; no refunds once an order processes | Cancel 48+ hours before renewal; membership fee non-refundable once paid |
| Availability | All 50 states | All 50 states |
| Best for | Out-of-pocket patients wanting a polished brand-name self-pay app | Insured patients seeking brand-name coverage help, or patients who want annual prepay savings |
Every price in this article comes from one of two places: the provider's public pricing page, or a completed intake quote from our monthly pricing refreshes (most recently October 2026). We walk each provider's signup flow to the final price screen rather than trusting the marketing headline, because "starting at" numbers in this category routinely leave out membership fees or apply only to a starter dose.
Clinical efficacy figures come from the published trial reports themselves. We pulled each number from the PubMed-indexed abstract or the manufacturer's announcement, and every figure below links to its source. Cancellation and refund claims come from each provider's published terms and help-center pages, with the access date noted. Where a policy detail wasn't published anywhere we could check, we say so rather than guessing.
Two honest limitations. We have not subscribed to either program as patients, so we can't tell you how fast the care team actually answers a 9 p.m. nausea message; we can only tell you what each platform promises in writing. And prices in this category move monthly, which is why we re-verify on a monthly cycle and stamp every article with a verification date.
Hims entered the GLP-1 space through a partnership with Novo Nordisk, the manufacturer of Wegovy and Ozempic. That relationship gives Hims direct access to brand-name semaglutide products. As of September 2026, the Hims catalog has expanded well beyond Wegovy: Wegovy pill ($149/mo at the 1.5mg starting dose, up to $299/mo at 9mg or 25mg), Wegovy pen ($199/mo at the starter doses, up to $349/mo at maintenance), Foundayo ($149/mo starter, escalating by dose), Zepbound (vial or KwikPen, $299/mo starter, up to $449/mo), Ozempic ($199/mo, off-label), and an oral Ozempic Pill added in September 2026 ($149/mo, off-label).
Hims discontinued oral compounded semaglutide in Q1 2026 as part of its shift to selling brand-name GLP-1s through the Novo Nordisk partnership (Hims investor announcement). The platform is now focused on FDA-approved brand-name options. All plans require a separate $149/month Hims Weight Loss Membership ($39 first month) on top of medication cost.
The support model is app-based and asynchronous. You can message your care team, but there are no scheduled coaching calls or behavioral curriculum. For patients who want to handle their own routine and just need a prescription and medication, that's fine. For patients who want more structure, Hims may feel light.
One genuine advantage: Hims is available in all 50 states, and the app is well-reviewed for usability.
Pros
Cons
Hims is best for: Patients paying out of pocket who want brand-name Wegovy and prefer a low-friction app experience.
Ro's program is built around one specific problem: getting insurance to pay for brand-name GLP-1 medications. Prior authorization for Wegovy or Zepbound is notoriously difficult. Insurers frequently deny on the first submission, and the appeals process requires clinical documentation that most patients don't know how to assemble. Ro includes insurance coordination as part of its program, meaning their care team actively handles prior auth submissions and insurer communication (more on exactly what that covers below).
Ro's brand-name catalog is comparable to Hims as of October 2026: Wegovy (pill or pen), Zepbound KwikPen, Foundayo (orforglipron), and now Ozempic off-label too. Ro exited compounded semaglutide in 2026 and no longer offers it in any state, so the catalog is now entirely brand-name.
Ro prices most of its catalog by dose rather than by how long you've been a member, which is worth reading carefully (per Ro's website, October 2026). Wegovy pill: $149 at 1.5mg, $199 at 4mg, $299 at 9mg or 25mg, the same ladder Hims uses. Foundayo: $149 at the 0.8mg starter dose, $149 at 2.5mg and $199 at 5.5mg (both temporarily reduced through December 31, 2026, from $199 and $299, mirroring Lilly's own promotion), and $299 at 9mg and above. Zepbound KwikPen: $299 at 2.5mg, $399 at 5mg, $449 at 7.5mg to 15mg, also matching Hims's ladder. The Wegovy pen is the one product with a genuine time-limited promo layered on top of dose: $199/month for roughly the first two fills at the 0.25mg and 0.5mg starter doses, then $349/month at 1mg to 2.4mg ($399/month for the 7.2mg Wegovy HD dose). Membership runs $149/month month-to-month, dropping to $99/month with a 3-month prepay, $89/month with 6 months, or $74/month with a 12-month prepay. The total monthly cost depends on dose, commitment, and whether insurance covers the medication.
The support layer is more built out than Hims's. Per Ro's site (July 2026), membership includes unlimited provider messaging, 24/7 access to the care team, 1:1 health coaching, weight and dose tracking tools, and what Ro describes as "side effect management and titration support" (ro.co/weight-loss). It's not a full behavioral program on the level of coaching-first providers, but it's meaningfully more structure than a bare prescription service.
Pros
Cons
Ro is best for: Patients with employer insurance or marketplace plans who want real help getting brand-name coverage approved. Also a good fit if you want tirzepatide (Zepbound) options.
Hims and Ro prescribe the same FDA-approved medications, so the efficacy question isn't "which platform works better." It's "which medication fits you," and that's where the trial data matters. All four medications below require a prescription, and a licensed clinician on either platform decides what's clinically appropriate for you.
One framing rule before the numbers: every figure here is a trial mean. Individual results vary widely around these averages, the trials enrolled different populations over different durations, and only some of these drugs have been compared head-to-head. Treat the numbers as a rough map, not a promised outcome.
| Medication | Available at | Pivotal trial | Mean weight change (drug vs placebo) | Duration |
|---|---|---|---|---|
| Wegovy pen (semaglutide 2.4mg injection) | Hims + Ro | STEP 1 | −14.9% vs −2.4% | 68 weeks |
| Zepbound (tirzepatide injection) | Hims + Ro | SURMOUNT-1 | −20.9% (15mg) vs −3.1% | 72 weeks |
| Wegovy pill (oral semaglutide 25mg) | Hims + Ro | OASIS 4 | ~−13.6% vs ~−2.4% | 64 weeks |
| Foundayo (orforglipron 36mg pill) | Hims + Ro | ATTAIN-1 | −11.2% vs −2.1% | 72 weeks |
The Wegovy pen was evaluated in STEP 1, a 68-week randomized trial of 1,961 adults with overweight or obesity. Participants on weekly semaglutide 2.4mg lost a mean of 14.9% of body weight versus 2.4% with placebo, and 86.4% of the semaglutide group achieved at least 5% weight loss versus 31.5% on placebo (Wilding et al., NEJM 2021).
The Wegovy pill (oral semaglutide 25mg) was evaluated in OASIS 4, a 64-week trial of 307 adults with obesity or overweight plus a weight-related condition. Mean weight loss was approximately 13.6% versus 2.4% for placebo regardless of adherence, rising to 16.6% among participants who stayed on treatment (Novo Nordisk, December 2025). The pill comes with a strict routine: first thing in the morning, empty stomach, limited water, then a 30-minute wait before food or other medications.
Zepbound's pivotal trial produced the largest published numbers in this catalog. SURMOUNT-1 randomized 2,539 adults over 72 weeks; mean weight change was −15.0% at the 5mg dose, −19.5% at 10mg, and −20.9% at 15mg, versus −3.1% for placebo. At the 15mg dose, 91% of participants achieved at least 5% weight reduction versus 35% on placebo (Jastreboff et al., NEJM 2022).
Tirzepatide activates both the GLP-1 and GIP receptors, which is the mechanistic explanation researchers give for the larger trial means. But cross-trial comparisons are inherently rough: SURMOUNT-1 and STEP 1 enrolled different populations over different durations, so the gap between 20.9% and 14.9% is suggestive, not definitive. For a deeper molecule-level comparison, see our tirzepatide vs semaglutide guide.
Foundayo (orforglipron) is the newest entry, FDA-approved in April 2026. In ATTAIN-1, a 72-week trial of 3,127 adults, the highest dose (36mg) produced a mean weight change of −11.2% versus −2.1% for placebo, with 54.6% of high-dose participants achieving at least 10% weight reduction versus 12.9% on placebo (Wharton et al., NEJM 2025).
That's the lowest trial mean of the four, but Foundayo has one concrete practical edge: no food, water, or timing restrictions, unlike the Wegovy pill. For patients whose real-world adherence would suffer under the Wegovy pill's morning rules, the effective difference may be smaller than the trial gap suggests. Our Foundayo vs Wegovy pill comparison covers that tradeoff in depth, including the manufacturer-funded indirect comparison between the two pills and why we treat it cautiously.
Since both platforms stock all four medications, the trial data doesn't pick a winner between them. What it does is sharpen the pricing question. If the tirzepatide trial means matter to you, compare Zepbound pricing specifically: Hims and Ro now price it identically by dose, $299/month medication at the starting 2.5mg dose, $399 at 5mg, and $449 at 7.5mg to 15mg. If you're choosing between the two pills, both platforms price them identically at the starting dose ($149/month medication), so the decision comes down to the medications themselves, not the platform.
Gastrointestinal side effects are the defining practical challenge of GLP-1 treatment, and they're a class effect, not a platform effect. In STEP 1, nausea and diarrhea were the most common adverse events, typically mild-to-moderate and transient, and 4.5% of semaglutide participants discontinued due to GI events versus 0.8% on placebo (Wilding et al., NEJM 2021). In SURMOUNT-1, GI events were likewise the most common adverse events, and 6.2% of participants on the 15mg tirzepatide dose discontinued due to adverse events versus 2.6% on placebo (Jastreboff et al., NEJM 2022). ATTAIN-1 reported the same pattern for orforglipron: mostly mild-to-moderate GI effects, with discontinuation due to adverse events ranging from 5.3% to 10.3% across doses versus 2.7% on placebo (Wharton et al., NEJM 2025).
So the question isn't whether you might feel queasy during dose escalation. Studies suggest a meaningful share of patients will. The question is what happens on each platform when you do.
On Hims, side-effect management runs through async messaging. You message the care team in the app, a provider reviews, and dose adjustments (slowing titration, holding a dose level longer) happen through that same message-based loop. Hims does not publish a response-time commitment for care messages, and we haven't independently tested turnaround.
On Ro, the published support model is broader. Ro lists unlimited provider messaging, 24/7 care team access, and "side effect management and titration support" as membership inclusions, alongside dose guidance toward a maintenance dose (ro.co/weight-loss, July 2026). As with Hims, there's no published guarantee of how fast a specific message gets answered, and we haven't tested it ourselves. But the structural difference is real: Ro's program is designed with titration support as a named feature, while Hims's is a leaner prescription-plus-messaging service.
Either way, the standard playbook applies: titrate on schedule rather than rushing, hydrate, favor smaller meals, and contact your prescriber promptly if symptoms are severe or persistent rather than pushing through. Severe or persistent symptoms warrant direct medical attention, not just an app message.
This is the clearest dividing line between the two platforms, so it deserves specifics.
Hims does not assist with prior authorization. The program is built for self-pay, full stop. If your insurance covers Wegovy or Zepbound, you and your outside prescriber would handle the PA process independently of Hims, and the $149/month Hims membership would still apply for anything you run through their platform.
Ro runs a dedicated insurance concierge. Per Ro's published insurance page (accessed September 2026), the concierge verifies your benefits, gathers the required clinical information, submits the prior authorization request, and communicates with your insurer directly. Ro estimates prior authorization typically takes about 1–2 weeks, with the full prescription-to-approval process running 1–3 weeks. If coverage is denied, Ro's team can pivot you toward an alternative FDA-approved option (ro.co/weight-loss/insurance).
Three fine-print details worth knowing before you count on the Ro pathway:
If a successful prior auth comes through, your medication cost drops to your plan's copay. Ro doesn't publish typical copay amounts, and what you'd pay depends entirely on your plan, so verify with your insurer rather than assuming a number.
Nobody signs up planning to cancel, but GLP-1 treatment is a months-to-years commitment and plans change. Here's what each provider publishes, with the caveat that terms can change and the binding version is whatever you agree to at checkout.
Hims requires subscription changes at least 48 hours before your next order processes. Canceling does not stop an order that has already begun processing, and per Hims's published refund policy, Hims does not provide refunds for orders that have shipped or entered processing (Hims help center: refund policy, accessed July 2026). For the weight loss program specifically, Hims's published terms state it does not refund partially used Weight Loss Membership or Medication Plan periods; medication plan refunds apply only if you cancel within 48 hours of initial signup or, for renewals, at least two days before the next billing date (Hims terms and conditions, accessed July 2026).
Ro lets you cancel the Ro Body membership from your account page or by emailing support, and requires cancellation "at least 48 hours in advance of your next renewal date" to avoid the next charge. Once paid, the membership fee is non-refundable, and after a properly timed cancellation you keep access through the end of the billing period you've paid for. On the medication side, Ro's terms state you're refunded if a medication is never prescribed, and a treatment request that expires before completion is refunded automatically (Ro terms of use, accessed July 2026).
Two things we could not verify and won't guess at. First, neither provider publishes an average refund processing time. Second, Ro's terms don't spell out whether the prepaid annual membership ($74/month billed annually) is prorated if you cancel mid-year; the general "non-refundable once paid" language suggests not, but confirm with Ro support before prepaying twelve months.
The practical takeaway is the same for both: the 48-hour cutoff is the rule that bites people. If you're leaning toward stopping, act the week before your renewal date, not the day of.
Both platforms operate in all 50 states as of our July 2026 verification, per each provider's website. That parity is worth a sentence of context: brand-name GLP-1s ship from licensed pharmacies nationwide, and both companies maintain clinician networks licensed in every state, so geography won't force your choice between these two the way it can with smaller telehealth providers.
The prescription itself always comes from a clinician licensed in your state, and eligibility is a clinical decision made during intake. Neither platform guarantees a prescription, and a legitimate provider never should.
Insurance handling is the clearest dividing line. Hims does not help with prior authorization; their model assumes you're paying out of pocket. Ro's entire value proposition for insured patients is the concierge covered above. If you have insurance, this difference matters more than any other factor.
Pricing structure has converged more than it used to. Wegovy pill, Foundayo, and Zepbound are now priced by dose at both platforms, off the same manufacturer self-pay ladders: $149 to $299 for the Wegovy pill, $299 to $449 for Zepbound. The Wegovy pen is the one product with a genuine time-limited promo at both platforms: $199/month on the lowest doses, jumping to $349–$399/month at maintenance. The real difference now is the membership: Hims charges a flat $149/month with no discount for prepaying, while Ro's drops as low as $74/month with a 12-month prepay. For patients confident they'll stay on treatment a year, Ro's prepay can undercut Hims; for patients who want no commitment, Hims's flat rate is simpler to budget.
Medication sourcing philosophy has fully converged. Both went heavily into FDA-approved brand-name options after the shortage resolution. Hims pulled back entirely from compounded offerings in Q1 2026, and Ro followed in 2026, exiting compounded semaglutide altogether. For patients who need a cash-pay compounded option, neither platform offers one; see Henry Meds or TrimRx for that.
The catalogs are now closely matched. Both Hims and Ro stock Wegovy (pill + pen), Foundayo, and Zepbound. Both now also list Ozempic for off-label use, though Hims prices it at $199/month (or $149/month for the new oral Ozempic Pill) while Ro's Ozempic listing runs closer to retail at roughly $900 to $1,100/month. The historical "Ro has Zepbound, Hims doesn't" gap closed in early 2026.
Support depth tilts toward Ro. Neither platform offers a full behavioral coaching program; that's what Found or Noom Med are designed for. But Ro's published membership inclusions (unlimited provider messaging, 24/7 care team access, 1:1 health coaching, titration support) go further than Hims's async messaging model, which is closer to a simple prescription service.
The right answer depends on which constraint is binding for you. Four common situations:
It's closer than it used to be, and for the pill it's now basically a tie. Both platforms price the Wegovy pill off the same Novo self-pay ladder: $149/month medication at the 1.5mg starting dose, up to $299/month at 9mg or 25mg. Where they diverge is the membership. Hims charges a flat $149/month ($39 in month one) with no way to lower it. Ro's membership starts at the same $149/month but drops to $99/month with a 3-month prepay, $89/month with 6 months, or $74/month with a 12-month prepay, which can make Ro cheaper over a long course even though the medication price is identical. The Wegovy pen follows the same pattern at both platforms: a $199/month promo on the two lowest doses that jumps to $349–$399/month at a maintenance dose. If you expect to stay on treatment a year or more and are comfortable prepaying, compare Ro's 12-month membership rate against Hims's flat rate for your expected dose; if you might stop early, Hims's no-commitment membership avoids the prepay risk, and a membership fee paid to Ro is non-refundable once charged.
Ro, and it isn't close, because Hims doesn't compete for this patient at all. Ro's concierge verifies benefits, submits the prior auth, and manages the insurer back-and-forth for the Wegovy pen, Zepbound pen, and Ozempic. A successful prior auth drops your medication cost to your plan's copay, which for an expensive brand-name injectable is the single biggest cost lever in this entire comparison. Even if your first submission is denied, Ro's team communicates with the insurer and can steer you toward an alternative covered option. Just remember the membership fee stays on your bill either way, and the oral pills aren't part of Ro's insurance pathway.
It's a tie, both on catalog and on price. Both platforms stock both FDA-approved oral GLP-1s and price them off the same manufacturer dose ladders: Wegovy pill $149/month at the starting dose, up to $299/month at 9mg or 25mg, at both Hims and Ro. Foundayo starts at $149/month at both as well (higher doses cost more at either platform). The only difference is the membership on top: Hims's flat $149/month versus Ro's tiers down to $74/month with a 12-month prepay. On the medication choice itself: the Wegovy pill posted the higher trial mean (~13.6% in OASIS 4) but demands a strict empty-stomach morning routine, while Foundayo (11.2% at the highest dose in ATTAIN-1) has no food or timing restrictions. Our Foundayo vs Wegovy pill guide breaks down that choice.
Both stock it, and at the starting dose they're tied. Hims and Ro both price Zepbound (vial or KwikPen) from $299/month medication, $448/month with membership, rising to $399/month at 5mg and $449/month at 7.5mg to 15mg, since both source pricing from Lilly's self-pay ladder. The exception that flips this: if your insurance plausibly covers Zepbound, Ro's concierge pathway applies to the Zepbound pen, and a covered pen beats any self-pay price. Tirzepatide posted the largest trial mean of any medication here (20.9% at 15mg in SURMOUNT-1), which is why demand for it stays high, but whether it's right for you is a prescriber conversation, not a numbers race.
Neither Hims nor Ro offers compounded medication anymore. Eden has the lowest month-to-month price we track, $99/month all-inclusive for compounded semaglutide injections at every dose with no membership. Henry Meds starts at $179/month all-inclusive for sublingual compounded semaglutide (injections from $197/month on a 12-month plan), and TrimRx charges a flat $199/month all-inclusive for compounded semaglutide injections at every dose. All three skip the separate membership fee structure. Compounded semaglutide contains the same active ingredient as brand-name versions but is not FDA-approved as a finished product, and it hasn't been evaluated in trials equivalent to STEP 1.
If you're still unsure which program fits your situation, the quiz at the top of this page takes about 90 seconds and factors in your insurance status, budget, and medication preferences. You can also see every provider's current numbers side by side in our GLP-1 pricing tool.
Hims
Wegovy pill from $149/mo, Foundayo from $149/mo, or Zepbound from $299/mo + $149/mo membership (October 2026)
Novo Nordisk partner with broad brand-name catalog: Wegovy pill + pen, Foundayo, Zepbound vial + KwikPen, and Ozempic.
Ro
$149/mo membership (as low as $74/mo with a 12-month prepay) + medication by dose (Wegovy pill $149–$299/mo, Wegovy pen $199 starter promo then $349–$399/mo, October 2026)
Insurance concierge verifies benefits and submits prior auth for Wegovy pen, Zepbound pen, and Ozempic.
Before choosing any GLP-1 program, consult your healthcare provider to confirm you're an appropriate candidate for semaglutide, tirzepatide, or orforglipron treatment. All of these are prescription-only medications, and the trial results above are group averages, not guarantees of individual results.